Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for N69605108 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
General Atlantic, L.P.
13G/A
|
7.6% |
8/14/2026
Event 6/30/2026
|
||
| General Atlantic, L.P. | 7.6% | |||
| General Atlantic PH B.V. | 7.6% | |||
| General Atlantic Cooperatief U.A. | 7.6% | |||
| General Atlantic Partners (Bermuda) IV, L.P. | 7.6% | |||
| General Atlantic Partners (Bermuda) EU, L.P. | 7.6% | |||
| General Atlantic Partners (Lux) SCSp | 7.6% | |||
| General Atlantic Cooperatief, L.P. | 7.6% | |||
| GAP Coinvestments III, LLC | 7.6% | |||
| GAP Coinvestments IV, LLC | 7.6% | |||
| GAP Coinvestments V, LLC | 7.6% | |||
| GAP Coinvestments CDA, L.P. | 7.6% | |||
| General Atlantic GenPar (Lux) SCSp | 7.6% | |||
| General Atlantic (Lux) S.a r.l. | 7.6% | |||
| General Atlantic GenPar (Bermuda), L.P. | 7.6% | |||
| GAP (Bermuda) L.P. | 7.6% | |||
|
Viking Global Investors LP
13G/A
|
5.6% |
5/15/2026
Event 3/31/2026
|
||
| Viking Global Investors LP | 5.6% | |||
| Viking Global Opportunities Parent GP LLC | 5.6% | |||
| Viking Global Opportunities GP LLC | 5.6% | |||
| Viking Global Opportunities Portfolio GP LLC | 5.6% | |||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.6% | |||
| Halvorsen Ole Andreas | 5.6% | |||
| Shabet Rose Sharon | 5.6% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (3) | ||||
|
LSP V Cooperatieve U.A.
13G/A
|
4.9% |
7/31/2026
Event 6/30/2026
|
||
| LSP V Cooperatieve U.A. | 4.9% | |||
| LSP V Management B.V. | 4.9% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
3.8% |
8/14/2025
Event 6/30/2025
|
||
| Venrock Healthcare Capital Partners III, L.P. | 3.8% | |||
| VHCP Co-Investment Holdings III, LLC | 3.8% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 3.8% | |||
| VHCP Management III, LLC | 3.8% | |||
| VHCP Management EG, LLC | 3.8% | |||
| Nimish Shah | 3.8% | |||
| Bong Y. Koh | 3.8% | |||
|
Bain Capital Life Sciences Fund, L.P.
13G/A
|
2.5% |
2/17/2026
Event 12/31/2025
|
||
| Bain Capital Life Sciences Fund, L.P. | 2.5% | |||
| BCIP Life Sciences Associates, LP | 0.3% | |||
| Bain Capital Life Sciences Opportunities III, LP | 1.5% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 32.0 | $1.02 k |
| 2026 Q2 | 132 | 65.5 M | $2.26 B |
| 2026 Q1 | 114 | 59.2 M | $1.67 B |
| 2025 Q4 | 109 | 59.0 M | $1.64 B |
| 2025 Q3 | 84 | 57.9 M | $1.44 B |
| 2025 Q2 | 62 | 45.0 M | $793 M |
| 2025 Q1 | 53 | 44.9 M | $706 M |
| 2024 Q4 | 55 | 44.6 M | $856 M |
| 2024 Q3 | 53 | 45.0 M | $834 M |
| 2024 Q2 | 38 | 43.0 M | $809 M |
| 2024 Q1 | 39 | 42.5 M | $982 M |
| 2023 Q4 | 40 | 40.8 M | $1.14 B |
| 2023 Q3 | 23 | 29.1 M | $607 M |
| 2023 Q2 | 22 | 28.9 M | $442 M |
| 2023 Q1 | 22 | 21.8 M | $174 M |
| 2022 Q4 | 26 | 21.3 M | $240 M |
| 2022 Q3 | 22 | 22.3 M | $174 M |
| 2022 Q2 | 21 | 22.4 M | $494 M |
| 2022 Q1 | 23 | 21.7 M | $397 M |
| 2021 Q4 | 24 | 21.7 M | $321 M |
| 2021 Q3 | 26 | 21.6 M | $380 M |
| 2021 Q2 | 30 | 22.0 M | $407 M |
| 2021 Q1 | 35 | 22.1 M | $617 M |